EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease

Na Ao, Jian Du, Shi Jin, Linna Suo, Jing Yang iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16043 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Na Ao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: Liaoning Provincial Education Department Fund General Project, The China Postdoctoral Science Foundation Fellowship Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is a common, highly heterogeneous condition that affects about a quarter of the world's population, with no approved drug therapy. Current evidence from preclinical research and a number of small clinical trials indicates that SGLT2 inhibitors could also be effective for MAFLD. MAFLD is associated with a higher risk of chronic liver disease and multiple extrahepatic events, especially cardiovascular disease (CVD) and chronic kidney disease (CKD). MAFLD is considered a more appropriate terminology than NAFLD because it captures the complex bidirectional interplay between fatty liver and metabolic dysfunctions associated with disease progression, such as obesity and type 2 diabetes mellitus (T2DM). SGLT2 inhibitors are antidiabetic drugs that block glucose reabsorption in the kidney proximal tubule. In this article, we reviewed current clinical evidence supporting the potential use of SGLT2 inhibitors as a drug therapy for MAFLD and discussed the possible cellular and molecular mechanisms involved. We also reviewed the clinical benefits of SGLT2 inhibitors against MAFLD‐related comorbidities, especially CVD, CKD and cardiovascular–kidney–metabolic syndrome (CKM). The broad beneficial effects of SGLT2 inhibitors support their use, likely in combination with other drugs, as a therapy for MAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Metabolic SyndromeNon-alcoholic Fatty Liver DiseaseSodium-Glucose Transporter 2 InhibitorsAnimalsHumansCardiovascular DiseasesObesityRenal Insufficiency, Chronic

Stichwörter der Autor:innen

cellular and molecular mechanismsmetabolic dysfunction‐associated fatty liver diseasesodium–glucose linked transporter 2 inhibitorstype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

ORCID-Profile: Jing Yang

Förderung

  • Liaoning Provincial Education Department Fund General Project
  • The China Postdoctoral Science Foundation Fellowship Program

Zitieren

APA

Ao, N., Du, J., Jin, S., Suo, L., & Yang, J. (2025). The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16043

Vancouver

Ao N, Du J, Jin S, Suo L, Yang J. The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16043

BibTeX
@article{Ao2025,
  author = {Ao, Na and Du, Jian and Jin, Shi and Suo, Linna and Yang, Jing},
  title = {The cellular and molecular mechanisms mediating the protective effects of sodium–glucose linked transporter 2 inhibitors against metabolic dysfunction‐associated fatty liver disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16043}
}
Kostenlos starten →